Results 101 to 110 of about 1,130 (117)

Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors

Oncologist, 2021
Richard F Riedel, Sebastian Bauer, Patrick Schöffski   +2 more
exaly  

The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation

ESMO Open, 2021
Julio Delgado
exaly  

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

European Journal of Cancer, 2021
Sebastian Bauer, Patrick Schöffski, Margaret Von Mehren   +2 more
exaly  

Avapritinib for Systemic Mastocytosis

Expert Review of Hematology, 2021
Prithviraj Bose, Srdan Verstovšek
exaly  

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy

Oncologist, 2021
Sebastian Bauer, Patrick Schöffski, Margaret Von Mehren   +2 more
exaly  

Indirect Treatment Comparisons of Avapritinib Versus Midostaurin for Patients with Advanced Systemic Mastocytosis

Future Oncology, 2022
Neil Roskell, Sérgio Iannazzo, Hollie Pilkington   +2 more
exaly  

Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy

Expert Review of Anticancer Therapy, 2021
Cesar Serrano
exaly